Claims
- 1. A chemically modified oligonucleotide having no more than about 27 nucleic acid base units, said oligonucleotide having the sequence (NxG3-4)QNX wherein X is 1 to 8 and Q is 1 to 6, wherein said oligonucleotide modulates mammalian telomere length.
- 2. The oligonucleotide of claim 1 which has at least one phosphorothioate linkage.
- 3. The oligonucleotide of claim 1 which has at least one 2′ modification of the sugar.
- 4. The oligonucleotide of claim 1 which is a chimeric oligonucleotide.
- 5. A method of modulating telomere length of a mammalian chromosome comprising contacting a mammalian chromosome with a chemically modified oligonucleotide having no more than about 27 nucleic acid base units, said oligonucleotide having the sequence (NxG3-4)QNX wherein X is 1 to 8 and Q is 1 to 6, wherein said oligonucleotide modulates mammalian telomere length.
- 6. The method of claim 5 which is carried out in vitro.
- 7. The method of claim 5 which is carried out in vivo.
- 8. A method for inhibiting the division of a malignant mammalian cell comprising contacting said malignant mammalian cell with a chemically modified oligonucleotide having no more than about 27 nucleic acid base units, said oligonucleotide having the sequence (NxG3-4)QNX wherein X is 1 to 8 and Q is 1 to 6, wherein said oligonucleotide modulates mammalian telomere length.
- 9. The method of claim 8 which is carried out in vitro.
- 10. The method of claim 8 which is carried out in vivo.
- 11. A method for modulating the effects of aging of a mammalian cell comprising contacting said mammalian cell with a chemically modified oligonucleotide having no more than about 27 nucleic acid base units, said oligonucleotide having the sequence (NxG3-4)QNX wherein X is 1 to 8 and Q is 1 to 6, wherein said oligonucleotide modulates mammalian telomere length.
- 12. The method of claim 11 which is carried out in vitro.
- 13. The method of claim 11 which is carried out in vivo.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of U.S. application Ser. No. 09/299,058, filed Apr. 23, 1999, which is a continuation of U.S. application Ser. No. 08/403,888 filed Jun. 12, 1995, which is U.S. Pat. No. 5,952,490, the U.S. national phase of PCT Application Serial No. PCT/US93/09297 filed Sep. 29, 1993, which is a continuation-in-part of U.S. application Ser. No. 07/954,185 filed Sep. 29, 1992, now abandoned, each of which is incorporated herein by reference in its entirety.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08403888 |
Jun 1995 |
US |
Child |
09299058 |
Apr 1999 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09299058 |
Apr 1999 |
US |
Child |
10038335 |
Jan 2002 |
US |
Parent |
07954185 |
Sep 1992 |
US |
Child |
PCT/US93/09297 |
Sep 1993 |
US |